


151460

W. ARCHIE BLEYER  
RONALD D. BARR  
Editors

PEDIATRIC ONCOLOGY

# Cancer in Adolescents and Young Adults



KAREN H. ALBRITTON  
MARIANNE PHILLIPS  
STUART E. SIEGEL  
Co-Editors

 Springer

# Contents

## 1 Introduction

W. Archie Bleyer, Karen H. Albritton,  
Lynn A.G. Ries, and Ronald Barr

1.1	Introduction	1
1.2	Epidemiology	2
1.2.1	Classification System	2
1.2.2	Incidence	3
1.2.2.1	Age-Specific Incidence	3
1.2.2.2	Gender-Specific Incidence	3
1.2.2.3	Ethnicity-Specific Incidence	4
1.2.2.4	Types of Cancer	4
1.2.2.5	Trends in Incidence	6
1.2.3	Mortality and Survival	7
1.2.3.1	Age- and Gender-Specific Mortality	7
1.2.3.2	Ethnicity-Specific Mortality	8
1.2.3.3	Trends in Mortality	8
1.2.4	Survival	9
1.2.4.1	Conditional Survival	12
1.2.5	Etiology and Risk Factors	15
1.3	Diagnosis	15
1.3.1	Signs and Symptoms	15
1.3.2	Radiologic and Pathologic Considerations	16
1.4	Treatment	17
1.4.1	Choice of Treatment Setting and Specialist	17
1.4.2	Surgery	18
1.4.3	Radiation Therapy	18
1.4.4	Chemotherapy	18
1.4.5	Psychosocial and Supportive Care	19
1.4.6	Lack of Participation in Clinical Trials	20
1.4.7	Quality of Survival	21
1.5	Summary	22
	References	23

## 2 History of Adolescent Oncology

Cameron K. Tebbi

### Epidemiology, Outcome, Access to Care and Role of Clinical Trials

2.1	Introduction	27
2.2	Background for Establishment of Adolescent/Young Adult Oncology as an Entity	29
2.3	Developments in the Psychosocial and Long-Term Care of Adolescent and Young Adult Oncology Patients	34
2.4	Summary	34
	References	34

## 3 Epidemiology and Etiology of Cancer in Adolescents and Young Adults

Jillian M. Birch and W. Archie Bleyer

3.1	Abstract	39
3.2	Introduction	40
3.3	Nosology and Cancer Spectrum	40
3.3.1	Diagnostic Classification	40
3.4	Incidence	41
3.4.1	Types of Cancers	42
3.4.2	Incidence Rates by Age and Diagnostic Group	45
3.4.3	Incidence by Gender	50
3.4.4	Temporal Trends in Incidence	50
3.5	Biological Differences	51
3.6	Etiology and Pathogenesis	52
3.6.1	Etiology	52
3.6.2	Genetic Predisposition and Genetic Susceptibility	54
3.7	Need for an Improved Classification System	55
3.8	Conclusions	55
	References	56

## 4 Access to Care Before and During Therapy

Karen H. Albritton and Tim Eden

4.1	Introduction	61
4.2	Access to Care Obstacles	62
4.2.1	Strategic/Financial Factors	63
4.2.2	Provider Issues	64
4.2.3	Personal Belief, Knowledge, Behavior	66
4.3	Delay in Diagnosis	66
4.4	Summary	67
	References	68

## 5 Older Adolescents and Young Adults with Cancer, and Clinical Trials: Lack of Participation and Progress in North America

W. Archie Bleyer, Troy Budd, and Michael Montello

5.1	Introduction	71
5.2	Deficit in Adolescent and Young Adult Participation in Clinical Trials	72
5.2.1	Race/Ethnicity	72
5.2.2	Gender	73
5.2.3	Residence	73
5.2.4	Individual Types of Cancer	73
5.3	Current Trends in Clinical Trial Participation by Older Adolescents and Young Adults with Cancer	73
5.4	Reasons for the Lack of Clinical Trial Participation by Older Adolescents and Young Adults with Cancer	73
5.5	Survival and Mortality Rates in Adolescents and Young Adults with Cancer	76
5.5.1	Survival Improvement: From Peak to Nadir	76
5.5.2	Survival by Gender and Ethnicity/Race	77
5.5.3	Survival by Individual Types of Cancer	77
5.5.4	Correlation of Survival Improvement and Mortality Reduction	77
5.6	Why the Lack of Progress in Older Adolescents and Young Adults with Cancer?	77
5.7	Summary	79
	References	80

## 6 Acute Lymphoblastic Leukemia

James Nachman, Giuseppe Masera, and W. Archie Bleyer

6.1	Introduction	83
6.2	Classification System and Methods	83
6.3	Incidence	84
6.3.1	Age-Specific Incidence	84
6.3.2	Gender-Specific Incidence	84
6.3.3	Racial/Ethnic Differences in Incidence	85
6.3.4	Incidence Trends	85
6.4	Risk Factors	85
6.5	Clinical Presentations and Molecular Biology	86
6.6	Treatment	88
6.7	Toxicity and Late Effects	91
6.8	Outcome	92
6.9	Summary and Conclusions	92
	References	96

## 7 Acute Myelogenous Leukemia

Ursula Creutzig and William G. Woods

7.1	Abstract	99
7.2	Introduction	99
7.3	Epidemiology/Etiology	100
7.3.1	Incidence	100
7.3.2	Etiology	100
7.3.3	Trends in survival	102
7.3.4	Prognostic factors	102
7.3.5	Treatment differences	103
7.4	Biology/Pathology	103
7.5	Diagnosis: Symptoms and Clinical Signs	104
7.6	Treatment/Management	104
7.7	Participation in Clinical Trials	105
7.8	Expected Outcome, Including Late Effects	106
7.9	Summary	107
	References	107

## 8 Hodgkin Lymphoma

Tanya M. Trippett, Alexis Mottl, Odile Oberlin, W. Archie Bleyer, and Louis S. Constine

8.1	Introduction	111
8.2	Epidemiology/Etiology	111
8.2.1	Incidence	111
8.2.1.1	Age-Specific Incidence	111
8.2.1.2	Gender-Specific Incidence	112
8.2.1.3	Racial/Ethnic Differences in Incidence	113
8.2.1.4	Trends in Incidence	113

8.3	Etiology/Risk Factors . . . . .	113
8.4	Pathology/Molecular Genetics . . . . .	115
8.5	Symptoms and Clinical Signs . . . . .	116
8.6	Diagnostic Testing . . . . .	116
	8.6.1 Hematology . . . . .	116
	8.6.2 Imaging . . . . .	117
	8.6.3 Surgery . . . . .	117
	8.6.4 Clinical Staging . . . . .	117
8.7	Treatment/Management . . . . .	118
	8.7.1 General Treatment Consideration . . . . .	118
	8.7.2 Specific Treatment Trials . . . . .	119
8.8	Outcome . . . . .	122
	8.8.1 Mortality . . . . .	122
	8.8.2 Survival . . . . .	122
	8.8.3 Specific Treatment Trials . . . . .	122
8.9	Follow-up/Late Effects . . . . .	122
8.10	Conclusions . . . . .	123
	References . . . . .	124

## 9 Non-Hodgkin Lymphoma

Catherine Patte, W. Archie Bleyer, and  
Mitchell S. Cairo

9.1	Introduction . . . . .	127
9.2	Epidemiology . . . . .	128
	9.2.1 Age-Specific Incidence . . . . .	128
	9.2.2 Incidence of Histologic Types . . . . .	129
	9.2.3 Gender-Specific Incidence . . . . .	129
	9.2.4 Racial/Ethnic Differences in Incidence . . . . .	129
9.3	Etiology/Risk Factors . . . . .	130
9.4	Histology/Cytogenetics . . . . .	130
9.5	Clinical Features . . . . .	132
9.6	Initial Work-Up and Staging . . . . .	132
9.7	B-Cell non-Hodgkin Lymphoma (B-Non-Hodgkin Lymphoma) . . . . .	134
	9.7.1 Burkitt Lymphoma . . . . .	134
	9.7.2 Diffuse Large B-Cell Lymphoma . . . . .	135
	9.7.3 Anaplastic Large Cell Lymphoma . . . . .	136
	9.7.3.1 Biology/Pathology . . . . .	136
	9.7.3.2 Treatment/Management of S-ALCL . . . . .	137
9.8	Lymphoblastic Lymphoma . . . . .	140
	9.8.1 Biology/Pathology . . . . .	140
	9.8.2 Treatment and Management . . . . .	141
9.9	Overall Survival . . . . .	143
9.10	Conclusions . . . . .	144
	References . . . . .	145

## 10 Central Nervous System Tumors in Adolescents and Young Adults

David A. Walker, Anne Bendel, Charles Stiller,  
Paul Byrne, and Michael Soka

10.1	Introduction . . . . .	152
10.2	Incidence, Pathology, and Etiology of CNS Tumors . . . . .	153
	10.2.1 Incidence of CNS Tumors in the Adolescent and Young Adult . . . . .	153
	10.2.2 United States Population Databases: SEER and CBTRUS . . . . .	153
	10.2.3 Data from the United Kingdom . . . . .	153
	10.2.4 Histology Age-Incidence Patterns . . . . .	154
	10.2.5 Etiology of CNS Tumors Adolescent and Young Adult . . . . .	156
	10.2.5.1 Environmental and Exogenous Risk Factors . . . . .	156
	10.2.5.2 Predisposing Conditions . . . . .	159
	10.2.5.3 Von Hippel-Lindau Syndrome . . . . .	159
	10.2.5.4 Tuberous Sclerosis . . . . .	161
	10.2.5.5 Li-Fraumeni Syndrome . . . . .	161
	10.2.5.6 Multiple Endocrine Neoplasia . . . . .	162
	10.2.5.7 Cowden Disease . . . . .	162
	10.2.5.8 Turcot Syndrome . . . . .	162
	10.2.5.9 Gardner's Syndrome . . . . .	162
	10.2.5.10 Others Other Conditions with Increased Risk of CNS Tumors . . . . .	162
	10.2.5.11 Familial Aggregation of Brain Tumors . . . . .	163
10.3	Presentation, Assessment, Treatment, and Outcome . . . . .	163
	10.3.1 Clinical Presentation . . . . .	163
	10.3.2 Symptomatology . . . . .	163
	10.3.3 Multiprofessional Priorities for Adolescent- and Young Adult Centered Care . . . . .	164
	10.3.4 Assessment and Management . . . . .	165
	10.3.4.1 Neurosurgery . . . . .	165
	10.3.4.2 Radiotherapy Techniques . . . . .	166
	10.3.4.3 Chemotherapy . . . . .	167
	10.3.4.4 Integrated Care . . . . .	169
	10.3.5 Intracranial GCTs – a Model Tumor of Adolescent and Young Adult Neurooncology Practice . . . . .	169
	10.3.5.1 Epidemiology of CNS GCTs . . . . .	169
	10.3.5.2 Tumor Markers and Pathology . . . . .	170
	10.3.5.3 Literature Review . . . . .	170

10.3.5.4	Phase 2 Studies in CNS GCTs . . . . .	171
10.3.5.5	Retrospective Institutional and Multi-Institutional Reports . . . . .	171
10.3.5.6	Registry Reports . . . . .	172
10.3.5.7	Phase 3 Trials . . . . .	172
10.3.5.8	Late Effects . . . . .	175
10.3.5.9	Quality of Life Reports . . . . .	175
10.4	Survival Rates for CNS Tumors; SEER, and European Data . . . . .	177
10.5	Conclusions . . . . .	178
	References . . . . .	178

## 11 Soft-Tissue Sarcomas

Karen H. Albritton, Andrea Ferrari,  
and Michela Casanova

11.1	Introduction . . . . .	185
11.2	Epidemiology/Etiology . . . . .	186
11.3	Biology/Pathology . . . . .	187
11.4	Diagnosis/Symptoms and Clinical Signs . . . . .	190
11.5	Treatment Management and Outcome . . . . .	190
11.5.1	Rhabdomyosarcoma . . . . .	190
11.5.2	Adult-Type STS . . . . .	195
11.5.3	Synovial Sarcoma . . . . .	197
11.6	Summary and Conclusions . . . . .	199
	References . . . . .	199

## 12 Bone Sarcomas

Michael S. Isakoff, Michael J. Harris,  
Mark C. Gebhardt, and Holcombe E. Grier

12.1	Introduction . . . . .	203
12.2	Osteosarcoma . . . . .	204
12.2.1	Epidemiology, Etiology, and Biology . . . . .	204
12.2.2	Pathology/Staging . . . . .	205
12.2.3	Diagnosis . . . . .	206
12.2.4	Treatment . . . . .	207
12.2.5	Late Effects . . . . .	208
12.3	Ewing Sarcoma . . . . .	209
12.3.1	Epidemiology and Etiology . . . . .	209
12.3.2	Biology and Pathology . . . . .	209
12.3.3	Diagnosis . . . . .	211
12.3.4	Treatment . . . . .	212
12.3.5	Late Effects . . . . .	214
12.4	Conclusions . . . . .	214
	References . . . . .	215

## 13 Malignancies of the Ovary

Jubilee Brown, Thomas Olson, and Susan Sencer

13.1	Introduction . . . . .	219
13.2	Epidemiology . . . . .	220
13.3	Pathology and Biology . . . . .	221
13.3.1	Germ-Cell Tumors . . . . .	221
13.3.2	Sex Cord-Stromal Tumors . . . . .	223
13.3.3	Epithelial Tumors . . . . .	223
13.3.4	Tumors of Low Malignant Potential . . . . .	223
13.3.5	Presenting Signs and Symptoms . . . . .	223
13.3.6	Diagnostic Work-up . . . . .	224
13.3.7	Surgical Management . . . . .	224
13.3.8	General Surgical Guidelines . . . . .	224
13.3.9	Staging . . . . .	226
13.3.10	GCTs: Surgical and Staging Considerations . . . . .	226
13.3.11	Teratomas: Surgical and Staging Considerations . . . . .	226
13.3.12	Dysgerminoma and Gonadoblastoma: Surgical and Staging Considerations . . . . .	226
13.3.13	Sex Cord Stromal Tumors: Surgical and . . . . . Staging Considerations . . . . .	227
13.3.14	Epithelial Ovarian Cancer: Surgical and Staging Considerations . . . . .	227
13.3.15	LMP Tumors: Surgical and Staging Considerations . . . . .	227
13.4	Treatment . . . . .	229
13.4.1	GCTs: Treatment Issues . . . . .	228
13.4.2	Dysgerminomas: Treatment Issues . . . . .	228
13.4.3	Sex Cord-Stromal Tumors: Treatment Issues . . . . .	228
13.4.4	Granulosa Cell Tumors: Treatment Issues . . . . .	229
13.4.5	Sertoli-Leydig Cell Tumors: Treatment Issues . . . . .	229
13.4.6	Epithelial Tumors: Treatment Issues . . . . .	230
13.4.7	Ovarian Tumors of LMP: Treatment Issues . . . . .	230
13.5	Outcomes . . . . .	231
13.5.1	Germ-Cell Tumors . . . . .	231
13.5.2	Sex Cord-Stromal Tumors . . . . .	231
13.5.3	Epithelial Tumors . . . . .	231
13.5.4	Tumors of LMP . . . . .	232
13.6	Conclusions . . . . .	232
	References . . . . .	234

**14 Testicular Tumors**

John W. Cullen and Robert Fallon

14.1	Introduction	237
14.2	Epidemiology and Etiology	237
14.3	Biology and Pathology	238
14.4	Clinical Symptoms and Evaluation	240
14.5	Staging and Risk Stratification	240
14.6	Treatment	241
14.7	Outcome	245
14.8	Late Effects	246
14.9	Conclusions	247
	References	247

**15 Non-Germ-Cell Genitourinary Tract Tumors**

Michael Leahy and W. Archie Bleyer

15.1	Introduction	249
15.2	Epidemiology and Etiology	250
15.3	Biology and Pathology	250
15.4	Clinical Presentations and Diagnosis	251
15.5	Treatment	251
15.6	Specific Tumors	252
15.6.1	Kidney Tumors	252
15.6.2	Urothelial and Bladder Tumors	253
15.6.3	Prostate Cancer	255
15.7	Comparative Survival Rates	256
15.8	Conclusions	256
	References	256

**16 Thyroid Cancer**

Steven G. Waguespack and Samuel A. Wells

16.1	Introduction	259
16.2	Epidemiology	260
16.3	Differentiated Thyroid Carcinoma	260
16.3.1	Epidemiology	260
16.3.2	Etiology/Pathology	260
16.3.3	Diagnosis and Clinical Presentation	262
16.3.4	Management	263
16.3.5	Late Effects	264
16.4	Medullary Thyroid Carcinoma	265
16.4.1	Epidemiology	265
16.4.2	Etiology/Pathology	265
16.4.3	Diagnosis and Clinical Presentation	266
16.4.4	Management	267
16.4.5	Late Effects	268
16.5	Conclusions	268
	References	268

**17 Malignant Melanoma**Cynthia E. Herzog, W. Archie Bleyer,  
and Alberto S. Pappo

17.1	Introduction	272
17.2	Epidemiology	272
17.2.1	Incidence Trends	272
17.2.2	Race/Ethnic Differences in Incidence	274
17.2.3	Gender Differences in Incidence	274
17.2.4	Incidence by Anatomic Location	274
17.2.5	Incidence Trends by Anatomic Location	275
17.2.6	Stage and Thickness Trends in Incidence	275
17.3	Etiology and Risk Factors	276
17.3.1	Xeroderma Pigmentosum	276
17.3.2	Immunosuppression	276
17.3.3	Familial Melanoma	277
17.3.4	Nevus Phenotype and Environmental Factors	278
17.3.5	The Sun and Other Ultraviolet Exposures	279
17.4	Clinical Presentation	279
17.5	Pathology	279
17.5.1	Primary Skin Tumor	279
17.5.2	Sentinel Node	281
17.5.3	Lymph Node Dissection	281
17.6	Surgery	281
17.6.1	Treatment of the Primary Tumor	282
17.6.2	Lymph Node Mapping	282
17.6.3	Lymph Node Dissection	283
17.6.4	Surgical Treatment of Spitz Nevus	283
17.7	Staging	283
17.7.1	Blood Tests	284
17.7.2	Imaging Studies	284
17.7.2.1	Ultrasound	284
17.7.2.2	Computed Tomography	284
17.7.2.3	Magnetic Resonance Imaging	284
17.7.2.4	Positron Emission Tomography	285
17.8	Non-surgical Therapy	285
17.8.1	Adjuvant therapy	285
17.8.1.1	Interferon	285
17.8.1.2	Radiotherapy	286
17.8.2	Treatment of Measurable Disease	286
17.8.2.1	Biotherapy	286
17.8.2.2	Bio-chemotherapy	286
17.8.2.3	Chemotherapy	286
17.8.2.4	Vaccine Therapy	286
17.9	Prognosis	286
17.10	Conclusions	287
	References	287

**18 Breast Cancer**

Marianne Phillips, Banu Arun, and W. Archie Bleyer

18.1	Introduction	293
18.2	Epidemiology	294
18.2.1	Incidence	294
18.2.1.1	Ethnic Differences in Incidence	294
18.2.1.2	Trends in Incidence	295
18.3	Diagnosis	295
18.4	Prognostic Characteristics	296
18.5	Treatment and Management	297
18.5.1	Surgery	297
18.5.2	Adjuvant Therapies	297
18.5.3	Adjuvant Chemotherapy	298
18.5.4	Adjuvant Endocrine Therapy	298
18.6	Outcome	299
18.6.1	Survival	299
18.6.2	Mortality	301
18.6.3	Race/Ethnic Differences in Mortality	302
18.6.4	Trends in Mortality	302
18.7	Special Considerations	302
18.7.1	Fertility Issues	302
18.7.2	Breast Cancer During Pregnancy	303
18.7.3	Risk Reduction in Women with Inherited Predisposition to Breast Cancer	304
18.7.4	Psychosocial Issues	305
18.8	Conclusions	306
	References	306

**19 Liver Tumors**Marcio H. Malogolowkin, Arthur Zimmermann,  
and Jack Plaschkes

19.1	Introduction	311
19.2	Epidemiology	312
19.2.1	Incidence	312
19.3	Risk Factors and Etiology	313
19.4	Pathology and Biology	314
19.4.1	HCC, Adult Type	314
19.4.2	Fibrolamellar HCC	314
19.4.3	Transitional Liver Cell Tumor	315
19.4.4	Hepatoblastoma	315
19.5	Genetic and Molecular Mechanisms of Hepatocarcinogenesis	316
19.6	Clinical Presentation and Diagnosis	316
19.6.1	Differential Diagnosis	317
19.6.1.1	Embryonal (Undifferentiated) Sarcoma of the Liver	317

19.6.1.2	Angiosarcoma and Cholangiocarcinoma	317
19.6.1.3	Benign Tumors	317
19.6.2	Tumor Staging	318
19.7	Treatment and Outcomes	319
19.7.1	Adults with HCC	319
19.7.2	Mortality and Survival	323
19.8	Liver Cancer in Adolescents and Young Adults	323
19.9	Future Perspectives	323
	References	325

**20 Colorectal Cancer**Wayne L. Furman, D. Ashley Hill, and  
Michael LaQuaglia

20.1	Introduction	331
20.2	Epidemiology	332
20.2.1	Incidence	332
20.2.2	Etiology	332
20.3	Biology/Pathology	333
20.4	Diagnosis: Symptoms and Clinical Signs	334
20.4.1	Staging	335
20.5	Treatment/Management	335
20.5.1	Surgery	336
20.5.2	Radiation Therapy	337
20.5.3	Adjuvant Chemotherapy	337
20.6	Outcome	337
20.7	Conclusions	338
	References	339

**21 Models of Care and Specialized Units**

Ian Lewis and Sue Morgan

21.1	Introduction	341
21.2	Aims of Care and the Patient Pathway	342
21.3	Teenagers and Young Adults Have Special Needs	342
21.3.1	What do Young People Say They Need?	343
21.4	Developing a Pathway to Meet the Needs of Teenagers and Young Adults	344
21.4.1	Centralization of Care and Access to Clinical Trials	344
21.4.2	Improving Psychological, Social, and Educational Support	344

21.4.3	Cancer-Specific or Teenagers-and-Young-Adults-Specific Multidisciplinary Teams: is There a Conflict? . . . . .	344
21.4.4	What Might a Single Pathway for Teenagers and Young Adults Look Like? . . . . .	345
<b>21.5</b>	<b>An Action Plan For Teenagers and Young Adults With Cancer</b> . . . . .	346
21.5.1	Past and Current Practice . . . . .	346
21.5.2	Patterns of Care . . . . .	346
21.5.2.1	Under 15 Years of Age . . . . .	347
21.5.2.2	Aged 15 to 19 Years . . . . .	347
21.5.2.3	Aged 20 Years and Over . . . . .	349
21.5.3	Paradigms of Care, Communication, and Interaction . . . . .	349
21.5.3.1	Children's Teams . . . . .	349
21.5.3.2	Adult Teams . . . . .	349
21.5.3.3	Teenage and Young Adult Teams . . . . .	350
21.5.3.4	Teenage and Young Adult Units and Team . . . . .	350
21.5.3.5	Virtual Units and Peripatetic Teams . . . . .	351
<b>21.6</b>	<b>Conclusions</b> . . . . .	351
	<b>References</b> . . . . .	352

**22 Drug Compliance by Adolescent and Young Adult Cancer Patients: Challenges for the Physician**

Benjamin Gesundheit, Mark L. Greenberg, Reuven Or, and Gideon Koren

<b>22.1</b>	<b>Introduction</b> . . . . .	353
22.1.1	Compliance: Definition and History, Cultural Changes During the Last 50 Years . . . . .	354
<b>22.2</b>	<b>Conclusions</b> . . . . .	355
22.2.1	Cancer, Compliance, and Adolescence: Definitions and Interactions . . . . .	355
22.2.1.1	Cancer and Adolescence . . . . .	355
<b>22.3</b>	<b>Assessment of Compliance</b> . . . . .	355
22.3.1	Indirect Methods . . . . .	356
22.3.2	Direct Methods . . . . .	356
22.3.3	Risk Factors and Predictors of Noncompliance . . . . .	357
22.3.3.1	Features of Treatment and Adverse Effects of Medication . . . . .	358
22.3.3.2	Demographic and Social Factors . . . . .	358
22.3.3.3	Parents' and Child's Knowledge and Attitudes . . . . .	358
<b>22.4</b>	<b>Discussion</b> . . . . .	359
	<b>References</b> . . . . .	361

**23 Psychological Support for Adolescents and Young Adults**

Christine Eiser and Aura Kuperberg

<b>23.1</b>	<b>Introduction</b> . . . . .	365
<b>23.2</b>	<b>From Diagnosis to Aftercare</b> . . . . .	365
23.2.1	Diagnosis . . . . .	366
<b>23.3</b>	<b>Pediatric-, Adolescent- or Adult-Based Care?</b> . . . . .	367
23.3.1	When Treatment Ends . . . . .	367
23.3.2	Follow-up Care . . . . .	367
<b>23.4</b>	<b>Long-Term Issues</b> . . . . .	368
23.4.1	Body Image . . . . .	368
23.4.2	Fertility . . . . .	368
23.4.3	Employment . . . . .	369
<b>23.5</b>	<b>Adolescence to Young Adulthood – The Developmental Transition</b> . . . . .	369
23.5.1	Unique Challenges of Adolescence . . . . .	369
23.5.1.1	Positive Body Image . . . . .	369
23.5.1.2	Sense of Identity and Independence . . . . .	369
23.5.1.3	Sexual Identity . . . . .	370
23.5.1.4	Future Career Goals . . . . .	370
<b>23.6</b>	<b>Treatment Approaches to Meet the Developmental Challenges of Adolescents and Young Adults</b> . . . . .	370
23.6.1	Impact Cancer, a Transition Model . . . . .	371
<b>23.7</b>	<b>Conclusions</b> . . . . .	372
	<b>References</b> . . . . .	372

**24 Psychosocial Support**

Brad J. Zebrack, Mark A. Chesler, and Anthony Penn

<b>24.1</b>	<b>Introduction</b> . . . . .	375
<b>24.2</b>	<b>Intellectual Issues</b> . . . . .	376
24.2.1	Information About Cancer Diagnosis, Prognosis, and Treatment . . . . .	376
24.2.2	Information Seeking . . . . .	376
<b>24.3</b>	<b>Practical Issues</b> . . . . .	376
24.3.1	The Hospitalization Experience, Including Pain and Painful Procedures . . . . .	376
24.3.2	School and Work . . . . .	377
<b>24.4</b>	<b>Interpersonal Issues</b> . . . . .	377
24.4.1	Relationship with Parents . . . . .	377
24.4.2	Relationships with Peers . . . . .	378
<b>24.5</b>	<b>Emotional Issues</b> . . . . .	378
24.5.1	Psychological Distress . . . . .	378
24.5.2	Posttraumatic Effects . . . . .	379
24.5.3	Coping . . . . .	380
24.5.4	The Importance of Social, Peer, and Family Support . . . . .	380
24.5.5	Support Groups . . . . .	380



24.6	Existential/Spiritual Issues . . . . .	381
24.6.1	Uncertainty . . . . .	381
24.7	Conclusion . . . . .	382
	References . . . . .	382

## 25 Health-Related Quality of Life

Ernest R. Katz, Tasha Burwinkle, James W. Varni,  
and Ronald D. Barr

25.1	Introduction . . . . .	387
25.2	Dimensions Used in Measuring HRQL . . . . .	388
25.3	Generic and Cancer-Specific Measures of HRQL . . . . .	389
25.4	Measuring HRQL in Adolescents vs Adults . . . . .	389
25.5	Self Report vs. Proxy Reports (i.e., Parent, Provider, or Caregiver) . . . . .	390
25.6	HRQL Measurement and Clinical Cancer Care . . . . .	390
25.7	Selected HRQL Measures for Adolescents and Young Adults . . . . .	392
25.8	Barriers to the Use of HRQL Measures and Proposed Solutions . . . . .	394
25.9	Facilitating Clinical Decision-Making with HRQL Data . . . . .	394
25.10	Risk Prediction . . . . .	395
25.11	Conclusions . . . . .	396
	References . . . . .	396

## 26 Rehabilitation and Exercise

Marilyn J. Wright

26.1	Introduction . . . . .	401
26.2	General Principles of Rehabilitation . . . . .	402
26.3	Rehabilitation and Exercise Needs . . . . .	402
26.3.1	Body Structure and Function . . . . .	403
26.3.2	Activity and Participation . . . . .	404
26.4	Intervention . . . . .	404
26.4.1	Physical Activity . . . . .	404
26.4.1.1	Precautions and Contraindication . . . . .	406
26.4.2	Other Specific Interventions . . . . .	406
26.4.3	Facilitating Participation . . . . .	408
26.4.4	Intervention for the Acutely Ill, Isolated, or Hospitalized Patient . . . . .	408
26.4.5	Palliative Care . . . . .	408
26.5	Conclusion . . . . .	409
	References . . . . .	409

## 27 Adolescent and Young Adult Cancer Survivors: Late Effects of Treatment

Smita Bhatia, Wendy Landier, Andrew A. Toogood,  
and Michael Hawkins

27.1	Introduction . . . . .	411
27.2	Medical Issues . . . . .	413
27.2.1	Late Mortality . . . . .	413
27.2.2	Second Primary Neoplasms . . . . .	413
27.2.2.1	Second Primary Neoplasms after Hodgkin Lymphoma . . . . .	414
27.2.2.2	Second Primary Neoplasms after Non-Hodgkin Lymphoma . . . . .	415
27.2.2.3	Second Primary Neoplasms after Testicular Cancer . . . . .	415
27.2.2.4	Second Primary Neoplasms after Breast Cancer . . . . .	415
27.2.3	Cardiovascular Function . . . . .	415
27.2.4	Pulmonary Function . . . . .	417
27.2.5	Endocrine Function . . . . .	418
27.2.6	Pituitary Function . . . . .	419
27.2.7	Gonadal Function . . . . .	419
27.2.8	Other Endocrinopathies . . . . .	420
27.2.9	Genitourinary Function . . . . .	420
27.2.9.1	Renal . . . . .	420
27.2.9.2	Bladder . . . . .	421
27.2.10	Gastrointestinal Function . . . . .	421
27.2.11	Musculoskeletal and Related Tissues . . . . .	422
27.3	Delivering Survivorship Care . . . . .	423
27.4	Recommendations for Screening . . . . .	423
27.5	Cancer Survivorship – Future Research Opportunities . . . . .	424
	References . . . . .	426

## 28 Ethical Issues for the Adolescent and Young Adult Cancer Patient: Assent and End-of-Life Care

Susan Shurin and Eric Kodish

28.1	Introduction . . . . .	431
28.2	Mark's Story at Diagnosis . . . . .	432
28.2.1	July 20, 1998 . . . . .	432
28.2.1.1	Case Report Presented by the Attending Physician . . . . .	432
28.2.1.2	Mark's Mother Sue's Diary Entry, July 20, 1998 . . . . .	432
28.2.1.3	Mark's Father George's Conversation at the Chatter- box Café, July 20, 1998 . . . . .	433
28.2.1.4	Mark's Email to his Girlfriend, July 20, 1998 . . . . .	433

28.3	<b>Mark's Story After Several Relapses</b> . . . . .	433
28.3.1	January 7, 2000 . . . . .	433
28.3.1.1	Case Report Presented by the Attending Physician at Tumor Board. . . . .	433
28.3.1.2	Sue's Diary Entry, December 31, 1999 . . . . .	433
28.3.1.3	George's Conversation with his Buddies at the Chatterbox Café, January 7, 2000 . . . . .	434
28.3.1.4	Mark's Email to his Girlfriend, January 1, 2000. . . . .	434
28.4	<b>Reflections on the Concept of Assent</b> . . . . .	434
28.4.1	Assent for Treatment and Assent for Research . . . . .	435
28.4.2	Assent at Diagnosis and Assent at Relapse . . . . .	435
28.4.3	Assent as Empowerment or Assent Negotiated? . . . . .	436
28.5	<b>Reflections on the Concept of Palliative Care</b> . . . . .	436
28.5.1	Professional and Family Roles . . . . .	436
28.5.2	Involvement of Adolescents in Decisions About Their Own Care . . . . .	437
28.5.3	Impact of Symptom Control on Therapeutic Decisions . . . . .	437
28.5.4	Palliative Care Issues at Diagnosis. . . . .	437
28.5.5	Palliative Care Issues at the End of Life . . . . .	438
28.6	<b>Biological Basis for Ongoing Development of Competence in Adolescents and Young Adults</b> . . . . .	438
28.6.1	An Alternate Scenario . . . . .	439
	<b>References</b> . . . . .	439

## 29 Access to Care after Therapy

Karen E. Kinahan, David R. Freyer, Beverly Ryan, and Mary Baron Nelson

29.1	<b>Introduction</b> . . . . .	443
29.2	<b>Survivors of Young Adult Cancer</b> . . . . .	443
29.3	<b>Young Adult Survivors of Childhood Cancer</b> . . . . .	444
29.3.1	Transition of Care: Background and Principles . . . . .	444
29.3.2	Transition of Care: Key Issues for Childhood Cancer Survivors . . . . .	445
29.3.3	Transitional Care Concerns Among Nurses in the Children's Oncology Group. . . . .	446

29.3.4	<b>Models of Transitional Care As Reported By Nurses in the COG</b> . . . . .	447
29.3.4.1	Model 1: Adult Practitioner Model. . . . .	448
29.3.4.2	Model 2: Resource Model . . . . .	448
29.3.4.3	Model 3: Switch Model . . . . .	448
29.3.4.4	Model 4: Comfort Model. . . . .	449
29.4	<b>Conclusions</b> . . . . .	449
	<b>References</b> . . . . .	449

## 30 Future Health of Survivors of Adolescent and Young Adult Cancer

Melissa M. Hudson and Kevin C. Oeffinger

30.1	<b>Introduction</b> . . . . .	451
30.2	<b>Healthcare of Cancer Survivors</b> . . . . .	452
30.2.1	Risk-Based Healthcare of Survivors . . . . .	454
30.2.2	Asymptomatic Survivors . . . . .	454
30.2.3	Symptomatic Survivors . . . . .	455
30.3	<b>Promoting Healthy Lifestyles</b> . . . . .	456
30.3.1	Health Behavior Counseling of the Adolescent/Young Adult Cancer Survivor . . . . .	456
30.3.2	Lifestyle Recommendations for the Adolescent/Young Adult Cancer Survivors. . . . .	457
30.3.3	Diet and Physical Activity . . . . .	457
30.3.4	Tobacco Use . . . . .	459
30.3.5	Alcohol. . . . .	460
30.3.6	Sun Protection . . . . .	462
30.3.7	Dental Care . . . . .	462
30.4	<b>Summary</b> . . . . .	462
	<b>References</b> . . . . .	463

## 31 Information and Resources for Young Adults and Adolescents with Cancer

David R. Freyer and Leonard J. Mattano

31.1	<b>Introduction</b> . . . . .	469
31.2	<b>The Value of Sharing Medical Information</b> . . . . .	469
31.3	<b>Methods of Sharing Medically Related Information</b> . . . . .	470
31.4	<b>The Expanding Role of Internet-Based Health and Medical Information Resources</b> . . . . .	470
31.5	<b>Using This Chapter</b> . . . . .	471
	<b>References</b> . . . . .	486

### 32 Making Ends Meet: Financial Issues from the Perspectives of Patients and Their Healthcare Team

David R. Freyer and Ronald D. Barr

32.1 Introduction	493
32.2 Younger Adolescents:	
the Financially Dependent Patient	494
32.2.1 Case Example	494
32.2.2 Major Financial Issues	494
32.3 Older Adolescents and Young Adults:	
the Financially Independent Patient	495
32.3.1 Case Example: The Young Adult	
On Therapy	496
32.3.2 Major Financial Issues	496
32.3.2.1 Health Insurance	496
32.3.2.2 Reduced Work and Loss	
of Income	496
32.3.3 Case Example: The Adolescent	
and Young Adult Survivor	
of Childhood Cancer	497
32.3.4 Major Financial Issues	497
32.3.4.1 Employment	497
32.3.4.2 Health and Life Insurance	500
32.3.4.3 Other Factors Threatening	
Financial Stability: Education	
and Marital Status	502
32.4 Conclusions	502
References	503

### 33 Challenges and Opportunities – The Way Ahead

W. Archie Bleyer, Karen Albritton, Stuart Siegel, Marianne Phillips, and Ronald Barr

33.1 Introduction	505
33.2 Current Status	506
33.3 Reasons for Lack of Progress	507
33.3.1 Personal/Patient	508
33.3.2 Family/Community	509
33.3.3 Health Professional	509
33.3.4 Societal/Cultural	511
33.4 Prioritization of Challenges	
and Potential Solutions	511
33.4.1 Personal/Patient	511
33.4.2 Family/Community	511
33.4.3 Health Professional	512
33.4.4 Societal/Cultural	512
33.5 Longer Time to Diagnosis in Adolescents	
and Young Adults than in Children	512
33.6 Place of Diagnosis and Treatment:	
Pediatric versus Adult Care Specialists	
and Facilities	513
33.7 Implications for Other Age Groups	515
33.8 International Perspectives	
and Global Challenge	515
33.9 Future Directions and Interim Solutions	516
33.10 Conclusions	517
References	518